Union européenne - français - EMA (European Medicines Agency)

pfizer europe ma eeig - ritlecitinib tosilate - alopecia areata - immunosuppresseurs - litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.

Canada - français - Health Canada

pfizer canada ulc - ritlécitinib (tosylate de ritlécitinib) - capsule - 50mg - ritlécitinib (tosylate de ritlécitinib) 50mg

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

deciphera pharmaceuticals (schweiz) ag - ripretinibum - comprimés - ripretinibum 50 mg, hypromellosi acetas succinas, cellulosum microcristallinum, lactosum monohydricum 179 mg, crospovidonum, silica colloidalis anhydrica, magnesii stearas, pro compresso. - gastrointestinale stromatumoren (gist) - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

astellas pharma ag - gilteritinibum - comprimés pelliculés - gilteritinibum 40 mg ut gilteritinibi hemifumaras, mannitolum, hydroxypropylcellulosum, hydroxypropylcellulosum substitutum humile, magnesii stearas, Überzug: hypromellosum, talcum, macrogolum 8000, e 171, e 172 (flavum), pro compresso obducto. - akute myeloide leukämie (aml) - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - entrectinibum - gélules - entrectinibum 100 mg, lactosum 65 mg, cellulosum microcristallinum, acidum tartaricum, hypromellosum, crospovidonum, magnesii stearas, silica colloidalis anhydrica, kapselhülle: hypromellosum, e 171, e 172 (flavum), drucktinte: lacca, propylenglycolum, ammoniae solutio concentrata, e 132, pro capsula. - solide tumoren, nicht-kleinzelliges bronchialkarzinom (nsclc) - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - entrectinibum - gélules - entrectinibum 200 mg, lactosum 130 mg, cellulosum microcristallinum, acidum tartaricum, hypromellosum, crospovidonum, magnesii stearas, silica colloidalis anhydrica, kapselhülle: hypromellosum, e 171, e 110 0.5543 mg, drucktinte: lacca, propylenglycolum, ammoniae solutio concentrata, e 132, pro capsula. - solide tumoren, nicht-kleinzelliges bronchialkarzinom (nsclc) - synthetika

Union européenne - français - EMA (European Medicines Agency)

deciphera pharmaceuticals (netherlands) b.v. - ripretinib - tumeurs stromales gastro-intestinales - agents antinéoplasiques - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.

Union européenne - français - EMA (European Medicines Agency)

astellas pharma europe b.v. - gilteritinib fumarate - leucémie, myéloïde, aiguë - agents antinéoplasiques - xospata est indiqué en monothérapie pour le traitement de patients adultes qui ont rechuté ou réfractaire de leucémie myéloïde aiguë (lma) avec une mutation flt3.

Union européenne - français - EMA (European Medicines Agency)

roche registration gmbh  - entrectinib - cancer; carcinoma, non-small-cell lung - agents antinéoplasiques - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.

Canada - français - Health Canada

deciphera pharmaceuticals. llc - riprétinib - comprimé - 50mg - riprétinib 50mg - antineoplastic agents